Clinical trials: Acute Myocardial Infarction With ST Elevation
- Condition Acute Myocardial Infarction With ST Elevation
- Funder type Industry (pharma, biotech, devices)
Myocardial Infarction
Safety and Efficacy Study of Adjunctive Antiplatelet Therapy Prior to Primary PCI in Patients With STEMI
Safety and efficacy of adjunctive antiplatelet therapy prior to primary percutaneous intervention (PCI) in patients with ST-Elevation Myocardial Infarction (STEMI)
- Trial name
- ERASE-MI (NCT00546260)
- Testing
- PRT060128 Potassium
- Where
- 31 sites in United States, Canada
- Volunteers
- 70 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Coronary Stenosis, Acute Coronary Syndrome
Multiomics and Imaging-based Assessment of Vulnerable Coronary Plaques in Acute Coronary Syndromes
The aim of Multiplaque clinical study is to assess the vulnerability degree of the atheromatous plaques, before and after a myocardial infarction (MI), based on multiomics analysis, associated with invasive and non-invasive data.
- Conditions
- Coronary Stenosis, Acute Coronary Syndrome, Acute Myocardial Infarction, Atheromatous Plaques
- Trial name
- MultiPlaque (NCT03391908)
- Testing
- cardiac imaging tests
- Where
- Romania
- Volunteers
- 100 people
- Sponsor
- Cardio Med Medical Center
Myocardial Infarction, Acute ST-Segment Elevation
Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment Thrombolysis in Myocardial Infarction - Study 25 (ExTRACT-TIMI25)
The primary objective of the study is to determine whether enoxaparin compared to unfractionated heparin will reduce the composite endpoint of all-cause mortality and non-fatal myocardial re-infarction within 30 days after…
- Trial name
- NCT00077792
- Testing
- Enoxaparin sodium (XRP4563)
- Where
- 48 sites in United States, Argentina and 46 more
- Volunteers
- 20,506 people
- Sponsor
- Sanofi
Acute Myocardial Infarction
TandemHeart to Reduce Infarct Size (TRIS Trial)
The purpose of this study is to determine if a device known as the TandemHeart® System (TandemHeart) can help limit heart damage and reduce serious complications after a certain type of heart attack (acute ST elevation anterior…
- Trial name
- TRIS (NCT02164058)
- Testing
- TandemHeart System, Percutaneous coronary intervention
- Sponsor
- CardiacAssist, Inc.
Myocardial Infarction
Ex Vivo Cultured Bone Marrow Derived Allogenic MSCs in AMI
This clinical trial aims to find out the safety and efficacy of adult mesenchymal stem cells in patients with myocardial infarction.
- Trial name
- NCT00883727
- Testing
- Stem cell, Plasmalyte A
- Where
- 4 sites in India
- Volunteers
- 20 people
- Sponsor
- Stempeutics Research Pvt Ltd
Myocardial Infarction (MI), Acute Coronary Syndromes (ACS)
A Clinical Trial to Demonstrate the Efficacy of Cangrelor
The primary objective of this study is to demonstrate that the efficacy of cangrelor is superior, or at least non-inferior, to that of clopidogrel in subjects requiring PCI.
- Trial name
- PCI (NCT00305162)
- Testing
- Cangrelor (P2Y12 inhibitor), clopidogrel (oral P2Y12 inhibitor)
- Where
- United States
- Volunteers
- 8,882 people
- Sponsor
- The Medicines Company
STEMI - ST Elevation Myocardial Infarction
Safety and Feasibility of Transcatheter Injectable Hydrogel in Acute STEMI Reperfusion Injury (REFINE Study)
The purpose of this clinical trial is to preliminarily evaluate the safety and feasibility of the transcatheter injectable protein alginate-based hydrogel developed and manufactured by Myomed Technology (Shaoxing) Co., Ltd.
- Trial name
- NCT07601997
- Testing
- Injectable protein alginate-based hydrogel, No additional intervention
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Myomed Technology (Shaoxing) Co., Ltd.
ST-segment Elevation Myocardial Infarction (STEMI), Cardiogenic Shock
The RECOVER IV Trial
The purpose of this study is to assess whether hemodynamic support with an Impella-based treatment strategy initiated prior to percutaneous coronary intervention (PCI) in patients with ST-Segment Elevation Myocardial Infarction…
- Trial name
- RECOVER IV (NCT05506449)
- Testing
- Impella CP®, Standard of Care
- Where
- 7 sites in United States, Denmark and 2 more
- Volunteers
- 4 people
- Sponsor
- Abiomed Inc.
Acute Coronary Syndrome
Long-term Follow-up of Antithrombotic Management Patterns in Acute Coronary Syndrome Patients in Russia
EPICOR-RUS is a multi-centre, observational, prospective, longitudinal cohort study which will include patients, in a real-life setting, who are hospitalized for acute coronary syndrome (ACS) within 24 hours of symptom onset and…
- Trial name
- EPICOR-RUS (NCT01373957)
- Where
- 19 sites in Russia
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
ST Elevation Myocardial Infarction
A Study to Evaluate the Safety and Efficacy of MEDI6012 in Acute ST Elevation Myocardial Infarction
This is a Phase 2b randomized, blinded, placebo controlled study to evaluate the efficacy, safety, PK/pharmacodynamic, and immunogenicity of repeat doses of MEDI6012 in adult participants presenting with acute STEMI (ST segment…
- Trial name
- REAL-TIMI 63B (NCT03578809)
- Testing
- MEDI6012
- Where
- 37 sites in Brazil, Czechia and 8 more
- Volunteers
- 593 people
- Sponsor
- MedImmune LLC
Myocardial Infarction
Study to Evaluate the Safety and Activity of BB3 to Treat Heart Attack
The study will evaluate the effect of BB3 to preserve myocardial (heart) tissue and function following myocardial infarction (heart attack).
- Trial name
- NCT01539590
- Testing
- BB3, Normal saline
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Angion Biomedica Corp
Myocardial Infarction (MI)
Efficacy and Safety Study of Proposed Biosimilar Product Reveliza vs Actilise in Patients With ST-segment Elevation Myocardial Infarction
Thi is is a multi-center, randomized, single-blind, parallel group clinical trial to evaluate the efficacy and safety of the intravenious thrombolysis with Revelise® (GENERIUM, Russia) in comparosin with the Actilyse® (Boehringer…
- Trial name
- NCT07146360
- Testing
- Revelise (GENERIUM, Russia), Actilyse® (Boehringer Ingelheim Pharma GmbH and Co.KG, Germany)
- Where
- 22 sites in Russia
- Volunteers
- 180 people
- Sponsor
- AO GENERIUM
Myocardial Infarction
A Study of RO4905417 in Patients With Non ST-Elevation Myocardial Infarction (Non-STEMI) Undergoing Percutaneous Coronary Intervention
This randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of RO4905417 in patients with non ST-elevation myocardial infarction (Non-STEMI) undergoing percutaneous coronary intervention (PCI).
- Trial name
- NCT01327183
- Testing
- Percutaneous Coronary Intervention (PCI), RO4905417
- Where
- 66 sites in United States, Canada and 2 more
- Volunteers
- 532 people
- Sponsor
- Hoffmann-La Roche
Coronary Artery Disease, Myocardial Ischemia
BIOFLOW III Asia Registry Orsiro Stent System
Cliflical evaluation of th' Orsiro LESS 10 diabetic subjects requiring coronary revasculariza t ion with Drug Eluting Stefl ts (DES) .880 subjects will be enrolled in this registry.
- Conditions
- Coronary Artery Disease, Myocardial Ischemia, Diabetes Mellitus Type 1 or 2
- Trial name
- NCT01941290
- Where
- 19 sites in China, India and 3 more
- Volunteers
- 387 people
- Sponsor
- BIOTRONIK Asia Pacific Pte Ltd
STEMI - ST Elevation Myocardial Infarction
ST-segment Elevation Not Associated With Acute Cardiac Necrosis (LESTONNAC)
Patients with chest pain and persistent ST segment elevation (STE) may not have acute coronary occlusions or serum troponin curves suggestive of acute necrosis.
- Trial name
- LESTONNAC (NCT05689970)
- Testing
- AI platform to detect ST elevation in ECG
- Where
- 7 sites in Spain
- Volunteers
- 420 people
- Sponsor
- Idoven 1903 S.L.
ST Elevation Myocardial Infarction
MGuard™ Prime Stent System Clinical Trial in Patients With Acute ST Elevation Myocardial Infarction
To evaluate the safety and efficacy of the MGuard™ Prime stent in the treatment of blocked arteries in coronary arteries in patients undergoing a stenting procedure due to having a heart attack.
- Trial name
- MASTER-II (NCT01869738)
- Testing
- MGuard Prime, (BMS/DES)
- Where
- 56 sites in United States, Belgium and 10 more
- Volunteers
- 310 people
- Sponsor
- InspireMD
Acute Coronary Syndrome
A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome
Ticagrelor is a new, reversible binding, anti-platelet medication. Anti-platelet medications work to prevent the formation of blood clots.
- Trial name
- PLATO (NCT00391872)
- Testing
- Ticagrelor, Clopidogrel
- Where
- 672 sites in United States, Argentina and 42 more
- Volunteers
- 18,624 people
- Sponsor
- AstraZeneca
Acute Coronary Syndrome
A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation
This is a randomized, double-blind, placebo-controlled, parallel group, multi-center study to evaluate initial safety and efficacy of GW856553 in subjects with NSTEMI.
- Trial name
- Solstice (NCT00910962)
- Testing
- GW856553
- Where
- 108 sites in United States, Australia and 7 more
- Volunteers
- 526 people
- Sponsor
- GlaxoSmithKline
Acute ST Elevation Myocardial Infarction
The Efficacy and Safety of rhTNK-tPA in Comparison With Alteplase(Rt-PA) as Fibrinolytic Therapy of Acute STEMI
This study is aiming to test the hypothesis that efficacy of rhTNK-tPA was not inferior to rt-PA with respect to the 30-day MACCE rates after fibrinolytic therapy for STEMI patients.
- Trial name
- NCT02835534
- Testing
- rhTNK-tPA, alteplase
- Where
- China
- Volunteers
- 818 people
- Sponsor
- CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.
Acute ST Segment Elevation Myocardial Infarction
Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial Infarction
The goal of the study was to evaluate the effect of single administration of RPH-104 at 80 mg and 160 mg on parameters of systemic inflammation and outcomes of the disease in subjects with ST-segment elevation myocardial…
- Trial name
- NCT04463251
- Testing
- RPH-104 80 mg
- Where
- 11 sites in United States, Russia
- Volunteers
- 102 people
- Sponsor
- R-Pharm Overseas, Inc.